2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow CNS Tumor: new trials by email Literature Review of CNS Tumor trials Research Report on CNS Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling avapritinib - Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm | Phase 1 / Phase 2 | Completed | Blueprint Medicines Corporation | 29 | 2022-02-24 | 2026-01-13 |
Central Nervous System Neoplasms (2) · Glioma (2) · Brain Neoplasms (1) · Meningioma (1) · Multiple Sclerosis (1) · Neoplasms (1) · Neurilemmoma (1) · Neurofibroma (1) · Neuroinflammatory Diseases (1) · Neuroma, Acoustic (1) · Recurrence (1)
Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Neuroepithelial (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Neuroectodermal Tumors (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Brain Diseases (1) · Central Nervous System Diseases (1)
Mn-PyC3A (1) · avapritinib (1)
Blueprint Medicines Corporation (1) · Reveal Pharmaceuticals Inc. (1)
United States (2) · Australia (1) · Austria (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · South Korea (1) · United Kingdom (1)
R44CA261240 (1)